Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Nov 1;8(3):CNS41.
doi: 10.2217/cns-2019-0012. Epub 2019 Nov 5.

The role of chemotherapy in the treatment of central neurocytoma

Margaret O Johnson  1 , John P Kirkpatrick  2 , Mallika P Patel  3 , Annick Desjardins  1 , Dina M Randazzo  1 , Henry S Friedman  1 , David M Ashley  1 , Katherine B Peters  1
Affiliations
Review

The role of chemotherapy in the treatment of central neurocytoma

Margaret O Johnson et al. CNS Oncol. .

Abstract

Aim: Central neurocytoma (CN) is a rare WHO grade II central nervous system (CNS) tumor. This is an update on chemotherapeutic agents used in its treatment. Patients & methods: An institutional review board-approved, chart review of patients seen at our institution resulted in a single case treated with chemotherapy and is herein included. We proceeded with a comprehensive literature review. Results: We identified 18 citations, representing 39 cases of adult and pediatric CN treated with chemotherapy. With the addition of our single case, the total number of recurrent CN patients treated with temozolomide (TMZ) is nine. Conclusion: There exists marked heterogeneity in chemotherapy used to treat CN. TMZ is incorporated into treatment regimens in the setting of tumor recurrence: its role merits further study.

Keywords: atypical neurocytoma; central neurocytoma; chemotherapy; drug therapy; neurocytoma; radiosensitizer; temozolomide; therapy.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure

This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors. KB Peters receives research funding from Eisai, Genentech, Merck, VBL Therapeutics, Agios, BioMimetix and Abbvie. A Desjardins also receives research funding from Genentech/Roche, Cellidex, Triphase Accelerator Corp., Lilly, Pfizer, Orbus Therapeutics and Symphogen. KB Peters serves as advisor/speaker/consultant for Novocure, Agios and Abbvie. A Desjardins serves as advisor/speaker/consultant for Genentech/Roche and Celgene. HS Friedman serves as advisor/speaker/consultant for Genentech/Roche. A Desjardins holds stock/ownership interest with IST GmbH. A Desjardins and HS Friedman hold letters of patent for Oncolytic Polio virus human tumors. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No funded writing assistance was utilized in the production of this manuscript.

References

    1. Louis DN, Perry A, Reifenberger G. et al. The 2016 World Health Organization Classification of tumors of the central nervous system: a summary. Acta Neuropathol. 131(6), 803–820 (2016). - PubMed
    1. Leenstra JL, Rodriguez FJ, Frechette CM. et al. Central neurocytoma: management recommendations based on a 35-year experience. Int. J. Radiat. Oncol. Biol. Phys. 67(4), 1145–1154 (2007). - PubMed

    2. •• Summarizes the use of chemotherapy in the treatment of central neurocytoma (CN).

    1. Vasiljevic A, Francois P, Loundou A. et al. Prognostic factors in central neurocytomas: a multicenter study of 71 cases. Am. J. Surg. Pathol. 36(2), 220–227 (2012). - PubMed
    1. Vasiljevic A, Champier J, Figarella-Branger D. et al. Molecular characterization of central neurocytomas: potential markers for tumor typing and progression. Neuropathology 33(2), 149–161 (2013). - PubMed
    1. Mccord M, Mukouyama YS, Gilbert MR, Jackson S. Targeting WNT signaling for multifaceted glioblastoma therapy. Front. Cell Neurosci. 11, 318 (2017). - PMC - PubMed

Substances